This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Urticaria

Using Doxepin for Urticaria

Sponsored by State University of New York - Upstate Medical University

About this trial

Last updated 3 years ago

Study ID

1576028

Status

Unknown status

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
18 to 65 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 2 years ago

What is this trial about?

Isolated urticaria in the emergency department is widely treated by physicians with histamine blocking agents such as diphenhydramine, cetirizine, and cimetidine. Doxepin is a tricyclic antidepressant that has been shown to have much higher concentrations of histamine blocking activity and therefore may be useful in treating urticaria. The purpose of this study is to compare the effectiveness of using doxepin verses a traditional medication, diphenhydramine (Benadryl), in the treatment of isolated urticaria in the emergency department.

What are the participation requirements?

Yes

Inclusion Criteria

- Between 18-65 years of age

- Presenting to Upstate Adult Emergency Department at either the Downtown or Community campuses.

- Diagnosed with isolated/acute urticaria

- Requires treatment with antihistamines to alleviate symptoms

No

Exclusion Criteria

- Pregnant women

- Prisoners

- Patients with altered mental status/have impaired decision-making capacity.

- Presenting with symptoms suggesting life threatening illness or anaphylaxis.

- Patients who have received any antihistamine (H1 antagonist) within the past 2 hours via any route of administration.

- Patients who have received an H2 antagonist within the past 2 hours.

- Patient received steroids by any route within the past 4 hours.

- Patient received epinephrine within the past 20 minutes.

- Patients currently taking concomitant p-glycoprotein inhibitors.

- Patients on any of the following CYP2D6 inhibitors: Bupropion, Fluoxetine, Paroxetine, Quinidine, Tipranavir.

- Patients with a history of serotonin syndrome.

- Patients currently taking another tricyclic antidepressant, selective serotonin reuptake inhibitor, and/or serotonin-norepinephrine reuptake inhibitor.

- Patients who have a condition where an antihistamine may be contraindicated.

- Patients with a contraindication to anticholinergic medications.

- History of adverse effects to tricyclic antidepressants or antihistamines.

- Patient who, based on their medical history or in the opinion of the clinician, have chronic urticaria, urticaria refractory to antihistamines, or dermatological disease that interferes with evaluation of a therapeutic response.

- Patients taking antileukotriene compounds (montelukast), calcineurin inhibitors (tacrolimus) or anti-serotonin agents (cyproheptadine)

Locations

Location

Status

Recruiting